Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2655–2657. doi: 10.1128/aac.40.11.2655

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

S L Moghazeh 1, X Pan 1, T Arain 1, C K Stover 1, J M Musser 1, B N Kreiswirth 1
PMCID: PMC163595  PMID: 8913484

Abstract

A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships.

Full Text

The Full Text of this article is available as a PDF (170.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bishai W. R., Graham N. M., Harrington S., Page C., Moore-Rice K., Hooper N., Chaisson R. E. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med. 1996 Jun 13;334(24):1573–1576. doi: 10.1056/NEJM199606133342404. [DOI] [PubMed] [Google Scholar]
  2. Bodmer T., Zürcher G., Imboden P., Telenti A. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1995 Feb;35(2):345–348. doi: 10.1093/jac/35.2.345. [DOI] [PubMed] [Google Scholar]
  3. Ellner J. J., Hinman A. R., Dooley S. W., Fischl M. A., Sepkowitz K. A., Goldberger M. J., Shinnick T. M., Iseman M. D., Jacobs W. R., Jr Tuberculosis symposium: emerging problems and promise. J Infect Dis. 1993 Sep;168(3):537–551. doi: 10.1093/infdis/168.3.537. [DOI] [PubMed] [Google Scholar]
  4. Iseman M. D. Evolution of drug-resistant tuberculosis: a tale of two species. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2428–2429. doi: 10.1073/pnas.91.7.2428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kapur V., Li L. L., Hamrick M. R., Plikaytis B. B., Shinnick T. M., Telenti A., Jacobs W. R., Jr, Banerjee A., Cole S., Yuen K. Y. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med. 1995 Feb;119(2):131–138. [PubMed] [Google Scholar]
  6. Kapur V., Li L. L., Iordanescu S., Hamrick M. R., Wanger A., Kreiswirth B. N., Musser J. M. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol. 1994 Apr;32(4):1095–1098. doi: 10.1128/jcm.32.4.1095-1098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kapur V., Whittam T. S., Musser J. M. Is Mycobacterium tuberculosis 15,000 years old? J Infect Dis. 1994 Nov;170(5):1348–1349. doi: 10.1093/infdis/170.5.1348. [DOI] [PubMed] [Google Scholar]
  8. Klemens S. P., Cynamon M. H. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1996 Feb;40(2):298–301. doi: 10.1128/aac.40.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lutfey M., Della-Latta P., Kapur V., Palumbo L. A., Gurner D., Stotzky G., Brudney K., Dobkin J., Moss A., Musser J. M. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med. 1996 Feb;153(2):837–840. doi: 10.1164/ajrccm.153.2.8564140. [DOI] [PubMed] [Google Scholar]
  10. Miller L. P., Crawford J. T., Shinnick T. M. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1994 Apr;38(4):805–811. doi: 10.1128/aac.38.4.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Musser J. M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995 Oct;8(4):496–514. doi: 10.1128/cmr.8.4.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mustaev A., Zaychikov E., Severinov K., Kashlev M., Polyakov A., Nikiforov V., Goldfarb A. Topology of the RNA polymerase active center probed by chimeric rifampicin-nucleotide compounds. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12036–12040. doi: 10.1073/pnas.91.25.12036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nolan C. M., Williams D. L., Cave M. D., Eisenach K. D., el-Hajj H., Hooton T. M., Thompson R. L., Goldberg S. V. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med. 1995 Sep;152(3):1067–1071. doi: 10.1164/ajrccm.152.3.7663785. [DOI] [PubMed] [Google Scholar]
  14. Ohno H., Koga H., Kohno S., Tashiro T., Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother. 1996 Apr;40(4):1053–1056. doi: 10.1128/aac.40.4.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M. J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647–650. doi: 10.1016/0140-6736(93)90417-f. [DOI] [PubMed] [Google Scholar]
  16. Williams D. L., Waguespack C., Eisenach K., Crawford J. T., Portaels F., Salfinger M., Nolan C. M., Abe C., Sticht-Groh V., Gillis T. P. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2380–2386. doi: 10.1128/aac.38.10.2380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yamamoto T., Amitani R., Suzuki K., Tanaka E., Murayama T., Kuze F. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 Feb;40(2):426–428. doi: 10.1128/aac.40.2.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yamane T., Hashizume T., Yamashita K., Konishi E., Hosoe K., Hidaka T., Watanabe K., Kawaharada H., Yamamoto T., Kuze F. Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo) 1993 Jan;41(1):148–155. doi: 10.1248/cpb.41.148. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES